

Table of Contents

List of Contributors	ix
----------------------------	----

Section A Introduction

A.1 General Introduction	3
<i>Hans Gerhard Vogel</i>	

Section B Clinical Pharmacokinetics

B.1 Introduction	7
<i>Jochen Maas</i>	
B.2 Dose Finding in Single Dose Studies by Allometric Scaling	9
<i>Tobias Pähler · Jochen Maas</i>	
B.3 Multiple Dose Studies	15
<i>Steven G. Woolfrey · James Gilmour Morrison</i>	
B.4 Dose Linearity and Proportionality	23
<i>Tanja Eisenblaetter · Lenore Teichert</i>	
B.5 Effects of Food Intake	41
<i>Roland Wesch</i>	
B.6 Special Populations: Profiling the Effect of Obesity on Drug Disposition and Pharmacodynamics	49
<i>James Gilmour Morrison</i>	
B.7 Special Populations: Renal Impairment	55
<i>Gerard Sanderink · Gareth Shackleton · Jochen Maas · James Gilmour Morrison</i>	
B.8 Special Populations: Hepatic Impairment	63
<i>Gerard Sanderink</i>	
B.9 Special Populations: Protein Binding Aspects	67
<i>Gareth Shackleton</i>	
B.10 The Human ADME Study	73
<i>Ulrich Kuerzel · Volker Krone · Manfred Zimmer · Gareth Shackleton</i>	
B.11 Synthesis of Radiolabeled Compounds for Clinical Studies	105
<i>Jens Atzrodt · John Allen</i>	

B.12 Drug–Drug Interaction Studies	119
<i>Wolfgang Schmider · Xavier Boulenc</i>	
B.13 In Vitro/In Vivo Correlation for Drug–Drug Interactions	133
<i>Xavier Boulenc · Wolfgang Schmider · Olivier Barberan</i>	
B.14 Specific Studies for Formulation Development	161
<i>Roland Wesch</i>	
B.15 Absolute and Relative Bioavailability	173
<i>Roland Wesch</i>	
B.16 Bioequivalence	181
<i>Graham Lockwood · Robert Kringle</i>	
B.17 Population Pharmacokinetics in Clinical Pharmacology	189
<i>Willi Weber · Jean Marie Martinez · Diether Rüppel · Graham Lockwood</i>	
B.18 Bioanalysis of Clinical Studies	207
<i>Joern Krause · Ronald Schmidt</i>	
B.19 Biomarker Definition and Validation During Drug Development	223
<i>Sibylle Hess · Marie Laure Ozoux · Martin Gerl</i>	
B.20 Toxicokinetics and Safety Ratios	245
<i>Karl Heinz Lehr</i>	
B.21 In Vitro/In Vivo Correlation for Transporters	251
<i>Dietmar Weitz</i>	
B.22 Relevance of Transporters in Clinical Studies	265
<i>Tanja Eisenblaetter</i>	
B.23 Specificities for Oncology Studies	291
<i>James Gilmour Morrison · Steven G. Woolfrey</i>	
B.24 Pharmacogenomics in and its Influence on Pharmacokinetics	297
<i>Guy Montay · Jochen Maas · Roland Wesch</i>	
B.25 PK/PD Approaches	313
<i>Diether Rüppel · Willi Weber</i>	
Section C Human Studies in Clinical Pharmacology	
C.1 Methodologies of PD Assessment: Scales	331
<i>Roman Görtelmeyer</i>	
C.2 Methodologies of Pharmacodynamic Assessment	347
<i>Claudia Pfeiffer · Peter Ruus</i>	

C.3	Pharmacodynamic Drug–Drug Interactions	367
	<i>Markus Hinder</i>	
C.4	Methodologies of Safety Assessment in Clinical Pharmacology	377
	<i>Werner Seiz</i>	
C.5	Pharmacodynamic Evaluation: Cardiovascular Methodologies	387
	<i>Christian de Mey · Markus Hinder</i>	
C.6	Pharmacodynamic Evaluation: CNS	423
	<i>Keith A. Wesnes · Helen Brooker</i>	
C.7	Pharmacodynamic Evaluation: Diabetes Methodologies	457
	<i>Reinhard H. A. Becker</i>	
C.8	Pharmacodynamic Evaluation: Inflammation/Immunology	483
	<i>Martin M. Schönharting</i>	
C.9	Pharmacodynamic Evaluation: Endocrinology	489
	<i>Jürgen Sandow</i>	
C.10	Pharmacodynamic Evaluation: Dermatology	523
	<i>Holger Köhler</i>	
C.11	Pharmacodynamic Evaluation: Oncology	533
	<i>Francois Lokiec</i>	
 Section D Regulations		
D.1	Development of Regulations for Submitting Pharmacogenomic Data to Authorities	547
	<i>Klaus Burger</i>	
D.2	Pharmacogenomic-Guided Drug Development	551
	<i>Klaus Burger</i>	
Index	559